A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors

Breast Cancer Research

Volumn 15, Issue 6, 2013, Pages

  Hudis, Clifford ^a   Swanton, Charles ^b   Janjigian, Yelena Y ^a   Lee, Ray ^c   Sutherland, Stephanie ^b,e   Lehman, Robert ^a   Chandarlapaty, Sarat ^a   Hamilton, Nicola ^a   Gajria, Devika ^a   Knowles, James ^c   Shah, Jigna ^c   Shannon, Keith ^c   Tetteh, Ernestina ^c   Sullivan, Daniel M ^d   Moreno, Carolina ^d   Yan, Li ^c   Han, Hyo S ^d  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c MERCK RESEARCH LABORATORIES   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e St Albans City Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; FUSED HETEROCYCLIC RINGS; MONOCLONAL ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; PROTEIN KINASE B;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLERGIC REACTION; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ESOPHAGUS CANCER; FATIGUE; FEMALE; FEVER; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; HYPOALBUMINEMIA; INFECTION; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; SOLID TUMOR; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CLINICAL TRIAL; DRUG ADMINISTRATION; GENETICS; MIDDLE AGED; MUTATION; PATHOLOGY; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 84887667026     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3577     Document Type: Article

References (21)

1. Menard S, Casalini P, Campiglio M, Pupa S, Agresti R, Tagliabue E. HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer. Ann Oncol 2001, 12:S15-S19.
2. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, Hung G, Robinson RA, Harris C, El-Naggar A, Slamon DJ, Phillips RN, Ross JS, Wolman SR, Flom KJ. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997, 15:2894-2904.
3. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008, 19:1523-1529. 10.1093/annonc/mdn169, 18441328.
4. Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, Beijersbergen RL, Valero V, Seoane J, Bernards R, Baselga J. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008, 68:9221-9230. 10.1158/0008-5472.CAN-08-1740, 2587064, 19010894.
5. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001, 93:1852-1857. 10.1093/jnci/93.24.1852, 11752009.
6. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007, 445:437-441. 10.1038/nature05474, 3025857, 17206155.
7. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12:395-402. 10.1016/j.ccr.2007.08.030, 17936563.
8. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6:117-127. 10.1016/j.ccr.2004.06.022, 15324695.
9. Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009, 15:429-440. 10.1016/j.ccr.2009.03.020, 19411071.
10. She QB, Chandarlapaty S, Ye Q, Lobo J, Haskell KM, Leander KR, DeFeo-Jones D, Huber HE, Rosen N. Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS One 2008, 3:e3065. 10.1371/journal.pone.0003065, 2516933, 18725974.
11. Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, Majumder PK, Baselga J, Rosen N. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011, 19:58-71. 10.1016/j.ccr.2010.10.031, 3025058, 21215704.
12. Yan L. MK-2206: A potent oral allosteric AKT inhibitor. Presented at the 100th Annual Meeting of the American Association for Cancer Research: April 18-22, 2009 2009, Denver, CO, Abstract #DDT01-01.
13. Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, Baird RD, Delgado L, Taylor A, Lupinacci L, Riisnaes R, Pope LL, Heaton SP, Thomas G, Garrett MD, Sullivan DM, de Bono JS, Tolcher AW. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 2011, 29:4688-4695. 10.1200/JCO.2011.35.5263, 22025163.
14. Ji Y, Li Y, Nebiyou Bekele B. Dose-finding in phase I clinical trials based on toxicity probability intervals. Clin Trials 2007, 4:235-244. 10.1177/1740774507079442, 17715248.
15. Biondo A, Yap TA, Yan L, Patnaik A, Fearen I, Baird RD, Papadopoulos KP, Delgado LM, Taylor A, Lupinacci L, Blackman SC, Decordova S, Tall M, Heaton S, Garrett MD, Sullivan D, De Bono JS, Tolcher AW. Phase I clinical trial of an allosteric AKT inhibitor, MK-2206, using a once weekly (QW) dose regimen in patients with advanced solid tumors. J Clin Oncol 2011, 29:abstract 3037.
16. Board RE, Wardley AM, Dixon JM, Armstrong AC, Howell S, Renshaw L, Donald E, Greystoke A, Ranson M, Hughes A, Dive C. Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Breast Cancer Res Treat 2010, 120:461-467. 10.1007/s10549-010-0747-9, 20107891.
17. Wong H, Leung R, Kwong A, Chiu J, Liang R, Swanton C, Yau T. Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2 metastatic breast cancer. Oncologist 2011, 16:1535-1546. 10.1634/theoncologist.2011-0165, 3233287, 22020213.
18. Morrow PK, Wulf GM, Ensor J, Booser DJ, Moore JA, Flores PR, Xiong Y, Zhang S, Krop IE, Winer EP, Kindelberger DW, Coviello J, Sahin AA, Nunez R, Hortobagyi GN, Yu D, Esteva FJ. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol 2011, 29:3126-3132. 10.1200/JCO.2010.32.2321, 3157979, 21730275.
19. Yan L, Rosen N, Arteaga C. Targeted cancer therapies. Chin J Cancer 2011, 30:1-4. 10.5732/cjc.010.10553, 21192839.
20. Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM, Group CS. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012, 366:109-119. 10.1056/NEJMoa1113216, 22149875.
21. Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Akthan G, Ellis C, Casey M, Florance A, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol 2012, 30:2585-2592. 10.1200/JCO.2011.35.6725, 22689807.